ABVX — Abivax S.A. stock price, charts and financials

QT76Abivax S.A.

Abivax S.A. (NASDAQ: ABVX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
124.78
-0.14-0.11%
OverviewShort InterestFilings
ABVXQT76Abivax S.A.·NASDAQ
124.78-0.11%
TA
Loading chart...
Signal & projected range
Analyst consensus risingHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
NUVL+0.00%$123.96CRNX+0.29%$83.76PTGX-3.19%$132.28IONS+5.25%$54.49PRAX-0.75%$305.51SYRE-3.46%$94.93KYMR-2.99%$100.31CYTK-0.88%$76.45
Snapshot
Index-P/E-EPS (ttm)-3.71Insider Own-Shs Outstand73.43MPerf Week-0.62%
Market Cap9.00BForward P/E-EPS next Y-3.53Insider Trans-Shs Float67.11MPerf Month-5.76%
Enterprise Value8.46BPEG0.36EPS next Q-1.26Inst Own-Short Float5.99%Perf Quarter6.42%
Income-409.56MP/S0.00EPS this Y-2.65%Inst Trans-Short Ratio1.98Perf Half Y10.02%
Sales5.00MP/B16.24EPS next Y7.24%ROA-57.52%Short Interest4.02MPerf YTD-7.36%
Book/sh-P/C-EPS next 5Y-ROE-165.19%52W High148.67 -16.07%Perf Year76.37%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-45.51%52W Low67.01 86.20%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.03% 3.99%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-22.47%Oper. Margin0.00%ATR (14)6.83Perf 10Y-
Dividend Ex-Date-Quick Ratio8.75Sales Y/Y TTM-Profit Margin0.00%RSI (14)49.20Recom2.08
Dividend Gr. 3/5Y-Current Ratio8.75EPS Q/Q-6.78%SMA20-6.08%Beta0.98Target Price158.00
Payout0.00%Debt/Eq0.10Sales Q/Q-100.00%SMA505.38%Rel Volume0.60Prev Close124.92
Employees80LT Debt/Eq0.07EarningsSep 21SMA2006.92%Avg Volume2.07MPrice124.78
IPO DateOct 20, 2023Option/ShortYes / YesEPS/Sales Surpr.24.89% 277.30%Net Debt/EBITDA1.89Volume1,235,341Change-0.11%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-24-26ReiteratedMorgan StanleyOverweight$132 → $180
Jul-09-26ReiteratedPiper SandlerOverweight$142 → $175
Jul-02-26ReiteratedTruist SecuritiesBuy$135 → $155
Jun-30-26UpgradeJefferiesHold → Buy$90 → $158
Jun-30-26ReiteratedBTIGBuy$150 → $175
Jun-03-26ReiteratedWolfe Research$176 → $136
Jun-02-26DowngradeJefferiesBuy → Hold$90
Jun-02-26ReiteratedMorgan StanleyOverweight$145 → $132
Jun-02-26UpgradeWedbushUnderperform → Neutral$110 → $90
Jun-02-26ReiteratedTruist SecuritiesBuy$140 → $135
Latest News
Jul-23-26
Jul-23-2602:06PM
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2Benzinga
Jul-17-26
Jul-17-2602:04PM
'Biotech Abivax re-engages investment bank Centerview for Big Pharma takeover talks' - La LettreBenzinga
Jul-16-26
Jul-16-2610:25AM
Abivax: Obefazimod Goes The Distance And So Does My Buy Ratingseekingalpha.com
Jul-10-26
Jul-10-2610:56AM
Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?zacks.com
06:10AM
Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBCcnbc.com
Jul-09-26
Jul-09-2601:35PM
9 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga
Jul-07-26
Jul-07-2607:15PM
3 Soaring Stocks That May Have More Upside Aheadfool.com
12:25PM
Abivax: Wall Street Catches Up to the Datamarketbeat.com
Jul-06-26
Jul-06-2604:05PM
Abivax Announces Closing of $920 Million Public Offeringglobenewswire.com
Jul-02-26
Jul-02-2607:42AM
Truist Securities Maintains Buy on Abivax, Raises Price Target to $155Benzinga
05:25AM
Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheetwsj.com
02:00AM
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)globenewswire.com
Jul-01-26
Jul-01-2607:02PM
Abivax nears $11 billion valuation after fundraising eases M&A pressurereuters.com
09:06AM
Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Sharesglobenewswire.com
08:56AM
Abivax announces trading resumption of its ordinary shares on Euronext Parisglobenewswire.com
Company

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue
500000000
Cost of Goods Sold Incl. D&A00005354393218
Gross Profit5000-53-54-39-32-18
Selling, General and Administrative Excl. Other3082423187655
Research and Development1122011591125157000
Other Operating Expense0-5-14-5-44-69-11-1
Operating Income-143-278-187-138-68-49-43-37-23
Interest Expense2232131574221
Unusual Expense
—————————
Non-Operating Income (Expense)0-6310-7123000
Net Income Before Taxes-165-373-191-160-64-50-46-39-23
Income Taxes-470000-3-5-5
Consolidated Net Income-160-379-191-160-64-50-43-34-19
Net Income From Continuing Operations-160-379-191-160-64-50-43-34-19
Net Income-160-379-191-160-64-50-43-34-19
EPS (Recurring)-3.71-5.25-3.03-3.71-3.34-3.25-2.99-2.81-1.84
EPS (Basic, Before Extraordinaries)-3.71-5.25-3.03-3.71-3.34-3.25-2.99-2.81-1.84
EPS (Diluted)-3.71-5.25-3.03-3.71-3.34-3.25-2.99-2.81-1.83
EBITDA-142-339-176-144-56-46-43-37-23
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
1,197.89————————
Gross Margin
100.00————————
Operating Margin
-2,860.00————————
Net Margin
-3,200.00————————
Shares Outstanding487063431915141210
Market Capitalization5,9899,440461460—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.